NOW RECRUITING: Patients with Pulmonary Arterial Hypertension (PAH) for IMPAHCT,
a Phase 2b/3 study evaluating AV-101. Learn more about the study.

George Eldridge

George has 25 years of experience in biotech, serving as CFO for several biotechnology companies including Curis, Targanta and Proteon. George’s extensive background in raising capital includes private, IPO and follow-on settings, investment banking and M&A.